Abstract | PURPOSE: EXPERIMENTAL DESIGN: RESULTS: CONCLUSIONS: Our results suggest that MTAT can impede primary PC-3 CaP growth at three different sites in vivo through induction of apoptosis, and can prevent the spread of cancer cells and target lymph node micrometastases in a concentration-dependent manner. MTAT, by targeting multiple antigens, can overcome heterogeneous antigen expression to kill small CaP cell clusters, thus providing a potent therapy for micrometastases.
|
Authors | Yong Li, Emma Song, Syed M Abbas Rizvi, Carl A Power, Julia Beretov, Chand Raja, Paul J Cozzi, Alfred Morgenstern, Christos Apostolidis, Barry J Allen, Pamela J Russell |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 15
Issue 3
Pg. 865-75
(Feb 01 2009)
ISSN: 1078-0432 [Print] United States |
PMID | 19188157
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- BLCA-38 monoclonal antibody
- Immunoconjugates
- MUC-1 monoclonal antibody
- Radioisotopes
- Urokinase-Type Plasminogen Activator
- Bismuth
|
Topics |
- Animals
- Antibodies, Monoclonal
(therapeutic use)
- Bismuth
- Cell Line, Tumor
- Disease Models, Animal
- Humans
- Immunoconjugates
(therapeutic use)
- Male
- Mice
- Mice, Nude
- Mice, SCID
- Neoplasm Metastasis
(prevention & control)
- Neoplasm Transplantation
- Prostatic Neoplasms
(pathology, therapy)
- Radioisotopes
(therapeutic use)
- Urokinase-Type Plasminogen Activator
(antagonists & inhibitors)
|